ZA200209946B - Compounds and compositions for delivering active agents. - Google Patents

Compounds and compositions for delivering active agents. Download PDF

Info

Publication number: ZA200209946B
Authority: ZA; South Africa
Prior art keywords: active agent; insulin; hormone; composition; interferon
Prior art date: 2000-06-29

Application number

ZA200209946A

Other languages

English (en)

Inventor

John J Weidner

Bruce F Variano

Shingai Majuru

Sataj Bhankarkar

William E Bay

Lynn Shields

Original Assignee

Emisphere Tech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-29

Filing date

2002-12-09

Publication date

2003-11-07

2002-12-09 Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc

2003-11-07 Publication of ZA200209946B publication Critical patent/ZA200209946B/en

Links

239000013543 active substance Substances 0.000 title claims abstract description 44
150000001875 compounds Chemical class 0.000 title claims abstract description 29
239000000203 mixture Substances 0.000 title claims abstract description 29
238000000034 method Methods 0.000 claims abstract description 11
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 18
239000000122 growth hormone Substances 0.000 claims description 15
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
102000004877 Insulin Human genes 0.000 claims description 9
108090001061 Insulin Proteins 0.000 claims description 9
102000014150 Interferons Human genes 0.000 claims description 9
108010050904 Interferons Proteins 0.000 claims description 9
229920000669 heparin Polymers 0.000 claims description 9
229940125396 insulin Drugs 0.000 claims description 9
-1 polyethylene Polymers 0.000 claims description 9
102000004196 processed proteins & peptides Human genes 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 8
229960002897 heparin Drugs 0.000 claims description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
239000003488 releasing hormone Substances 0.000 claims description 6
229920001184 polypeptide Polymers 0.000 claims description 5
229920001282 polysaccharide Polymers 0.000 claims description 5
239000005017 polysaccharide Substances 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
241000283690 Bos taurus Species 0.000 claims description 4
229920001499 Heparinoid Polymers 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
150000004676 glycans Chemical class 0.000 claims description 4
239000002554 heparinoid Substances 0.000 claims description 4
229940025770 heparinoids Drugs 0.000 claims description 4
229940088597 hormone Drugs 0.000 claims description 4
239000005556 hormone Substances 0.000 claims description 4
150000002632 lipids Chemical class 0.000 claims description 4
229910052708 sodium Inorganic materials 0.000 claims description 4
239000011734 sodium Substances 0.000 claims description 4
102000055006 Calcitonin Human genes 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 3
229920000045 Dermatan sulfate Polymers 0.000 claims description 3
229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
102000000589 Interleukin-1 Human genes 0.000 claims description 3
108010002352 Interleukin-1 Proteins 0.000 claims description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
229940047124 interferons Drugs 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
102000000588 Interleukin-2 Human genes 0.000 claims description 2
108010002350 Interleukin-2 Proteins 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims 10
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 5
239000003055 low molecular weight heparin Substances 0.000 claims 5
229940127215 low-molecular weight heparin Drugs 0.000 claims 5
102000018997 Growth Hormone Human genes 0.000 claims 4
108010051696 Growth Hormone Proteins 0.000 claims 4
102000003982 Parathyroid hormone Human genes 0.000 claims 4
108090000445 Parathyroid hormone Proteins 0.000 claims 4
229960000265 cromoglicic acid Drugs 0.000 claims 4
239000012634 fragment Substances 0.000 claims 4
239000000199 parathyroid hormone Substances 0.000 claims 4
229960001319 parathyroid hormone Drugs 0.000 claims 4
102000003951 Erythropoietin Human genes 0.000 claims 3
108090000394 Erythropoietin Proteins 0.000 claims 3
229940105423 erythropoietin Drugs 0.000 claims 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 3
101001011741 Bos taurus Insulin Proteins 0.000 claims 2
229920002567 Chondroitin Polymers 0.000 claims 2
101800000414 Corticotropin Proteins 0.000 claims 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
229930105110 Cyclosporin A Natural products 0.000 claims 2
108010036949 Cyclosporine Proteins 0.000 claims 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 2
108010029961 Filgrastim Proteins 0.000 claims 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 2
102000004547 Glucosylceramidase Human genes 0.000 claims 2
108010017544 Glucosylceramidase Proteins 0.000 claims 2
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 2
101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 2
101000976075 Homo sapiens Insulin Proteins 0.000 claims 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
102000002265 Human Growth Hormone Human genes 0.000 claims 2
108010000521 Human Growth Hormone Proteins 0.000 claims 2
239000000854 Human Growth Hormone Substances 0.000 claims 2
102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
102400000050 Oxytocin Human genes 0.000 claims 2
101800000989 Oxytocin Proteins 0.000 claims 2
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 2
239000004698 Polyethylene Substances 0.000 claims 2
108010005991 Pork Regular Insulin Proteins 0.000 claims 2
102000013275 Somatomedins Human genes 0.000 claims 2
102000005157 Somatostatin Human genes 0.000 claims 2
108010056088 Somatostatin Proteins 0.000 claims 2
102000036693 Thrombopoietin Human genes 0.000 claims 2
108010041111 Thrombopoietin Proteins 0.000 claims 2
108010059993 Vancomycin Proteins 0.000 claims 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 2
108010004977 Vasopressins Proteins 0.000 claims 2
102000002852 Vasopressins Human genes 0.000 claims 2
239000003429 antifungal agent Substances 0.000 claims 2
229940121375 antifungal agent Drugs 0.000 claims 2
239000000427 antigen Substances 0.000 claims 2
102000036639 antigens Human genes 0.000 claims 2
108091007433 antigens Proteins 0.000 claims 2
239000004599 antimicrobial Substances 0.000 claims 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 2
230000001746 atrial effect Effects 0.000 claims 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims 2
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 2
229960001265 ciclosporin Drugs 0.000 claims 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
229960000258 corticotropin Drugs 0.000 claims 2
229930182912 cyclosporin Natural products 0.000 claims 2
229960000958 deferoxamine Drugs 0.000 claims 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
229960004177 filgrastim Drugs 0.000 claims 2
229940028334 follicle stimulating hormone Drugs 0.000 claims 2
229940045644 human calcitonin Drugs 0.000 claims 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 2
229940094443 oxytocics prostaglandins Drugs 0.000 claims 2
229960001723 oxytocin Drugs 0.000 claims 2
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
229920000573 polyethylene Polymers 0.000 claims 2
150000003180 prostaglandins Chemical class 0.000 claims 2
108010068072 salmon calcitonin Proteins 0.000 claims 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
229960000553 somatostatin Drugs 0.000 claims 2
229960003165 vancomycin Drugs 0.000 claims 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
229960003726 vasopressin Drugs 0.000 claims 2
239000011782 vitamin Substances 0.000 claims 2
229940088594 vitamin Drugs 0.000 claims 2
229930003231 vitamin Natural products 0.000 claims 2
235000013343 vitamin Nutrition 0.000 claims 2
JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 claims 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
GCVGCXMTCJMBHY-UHFFFAOYSA-M 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O GCVGCXMTCJMBHY-UHFFFAOYSA-M 0.000 claims 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 1
102000006771 Gonadotropins Human genes 0.000 claims 1
108010086677 Gonadotropins Proteins 0.000 claims 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
102000015696 Interleukins Human genes 0.000 claims 1
108010063738 Interleukins Proteins 0.000 claims 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
239000003086 colorant Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000007884 disintegrant Substances 0.000 claims 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
239000002622 gonadotropin Substances 0.000 claims 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 1
239000000314 lubricant Substances 0.000 claims 1
150000004682 monohydrates Chemical class 0.000 claims 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000008363 phosphate buffer Substances 0.000 claims 1
CEYGNZMCCVVXQW-UHFFFAOYSA-N phosphoric acid;propane-1,2-diol Chemical compound CC(O)CO.OP(O)(O)=O CEYGNZMCCVVXQW-UHFFFAOYSA-N 0.000 claims 1
239000004014 plasticizer Substances 0.000 claims 1
229960004063 propylene glycol Drugs 0.000 claims 1
235000013772 propylene glycol Nutrition 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 3
150000001413 amino acids Chemical class 0.000 description 13
230000004888 barrier function Effects 0.000 description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000007787 solid Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102000014429 Insulin-like growth factor Human genes 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
150000003948 formamides Chemical class 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200209946A 2000-06-29 2002-12-09 Compounds and compositions for delivering active agents. ZA200209946B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US21489300P	2000-06-29	2000-06-29

Publications (1)

Publication Number	Publication Date
ZA200209946B true ZA200209946B (en)	2003-11-07

Family

ID=22800813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200209946A ZA200209946B (en)	2000-06-29	2002-12-09	Compounds and compositions for delivering active agents.

Country Status (24)

Country	Link
US (1)	US7351741B2 (de)
EP (1)	EP1299348B1 (de)
JP (1)	JP2004521857A (de)
KR (1)	KR100828668B1 (de)
CN (1)	CN100482637C (de)
AT (1)	ATE391708T1 (de)
AU (3)	AU7315301A (de)
BR (1)	BR0112311A (de)
CA (1)	CA2411754C (de)
CY (1)	CY1108532T1 (de)
CZ (1)	CZ303736B6 (de)
DE (1)	DE60133555T2 (de)
DK (1)	DK1299348T3 (de)
ES (1)	ES2306719T3 (de)
HK (1)	HK1054918A1 (de)
IL (1)	IL153297A0 (de)
MX (1)	MXPA02012855A (de)
NZ (1)	NZ523017A (de)
PT (1)	PT1299348E (de)
RU (1)	RU2326110C2 (de)
SK (1)	SK1182003A3 (de)
UA (1)	UA80248C2 (de)
WO (1)	WO2002002509A1 (de)
ZA (1)	ZA200209946B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358504B1 (en) *	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US7227033B2 (en)	2002-01-09	2007-06-05	Emisphere Technologies, Inc.	Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
WO2002019969A2 (en) *	2000-09-06	2002-03-14	Emisphere Technologies Inc.	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
JP5196701B2 (ja)	2001-11-29	2013-05-15	エミスフィアーテクノロジーズインコーポレイテッド	クロモリンナトリウムの経口投与用製剤
US20030198666A1 (en) *	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
MXPA04008068A (es)	2002-02-20	2004-11-26	Lilly Co Eli	Metodo para administrar moleculas de glp-1.
NZ541058A (en)	2003-01-06	2008-06-30	Emisphere Tech Inc	Night-time oral insulin therapy
JP2006519881A (ja) *	2003-03-06	2006-08-31	エミスフィアーテクノロジーズインコーポレイテッド	経口インスリン治療及びプロトコール
WO2004080401A2 (en) *	2003-03-06	2004-09-23	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
MXPA06001353A (es)	2003-08-08	2006-05-04	Abgenix Inc	Anticuerpos dirigidos a hormona paratiroides(pth) y usos de los mismos.
ES2278346T3 (es)	2003-08-20	2007-08-01	Eli Lilly And Company	Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
ATE361294T1 (de)	2003-08-20	2007-05-15	Lilly Co Eli	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
US20050203001A1 (en)	2004-03-05	2005-09-15	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
WO2005027960A1 (en) *	2003-09-25	2005-03-31	Cangene Corporation	Liquid human growth hormone formulation containing polyethylene glycol
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
KR20070008720A (ko)	2004-05-06	2007-01-17	에미스페어 테크놀로지스, 인코포레이티드	습윤 헤파린의 고체 투여형
EP2279732B1 (de)	2004-05-14	2019-03-20	Emisphere Technologies, Inc.	Verbindungen und Zusammensetzungen zur Wirkstofffreisetzung
NZ551241A (en)	2004-05-14	2010-08-27	Emisphere Tech Inc	Aryl ketone compounds and compositions for delivering active agents
US9498487B2 (en)	2004-05-19	2016-11-22	Emisphere Technologies, Inc.	Topical cromolyn formulations
CN1968699B (zh)	2004-05-19	2010-12-15	爱密斯菲尔科技公司	阿昔洛韦制剂
WO2006017541A2 (en) *	2004-08-03	2006-02-16	Emisphere Technologies, Inc.	Antidiabetic oral insulin-biguanide combination
JP4636839B2 (ja) *	2004-09-24	2011-02-23	パナソニック株式会社	電子デバイス
GB0427603D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
BRPI0517574A (pt) *	2004-12-29	2008-10-14	Emisphere Tech Inc	formulação farmacêutica, método para tratar ou prevenir hipercalcemia e método para preparar formulação farmacêutica
WO2006076692A1 (en) *	2005-01-12	2006-07-20	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
WO2007011958A2 (en)	2005-07-15	2007-01-25	Emisphere Technologies, Inc.	Intraoral dosage forms of glucagon
KR20080072830A (ko) *	2005-11-04	2008-08-07	젠타 인코포레이티드	약제학적 갈륨 조성물 및 이를 이용한 방법
US8927015B2 (en)	2006-04-12	2015-01-06	Emisphere Technologies, Inc.	Formulations for delivering insulin
US8771712B2 (en)	2006-05-09	2014-07-08	Emisphere Technologies, Inc.	Topical administration of acyclovir
WO2008003050A2 (en)	2006-06-28	2008-01-03	Emisphere Technologies, Inc.	Gallium nitrate formulations
EP2057112B1 (de) *	2006-08-31	2018-12-19	Emisphere Technologies, Inc.	Verbindungen und zusammensetzungen zur wirkstofffreisetzung
ES2841379T3 (es)	2007-03-13	2021-07-08	Jds Therapeutics Llc	Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CA3014633C (en) *	2007-10-08	2022-05-17	Aurinia Pharmaceuticals Inc.	Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
IL188647A0 (en)	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2010021752A1 (en) *	2008-08-21	2010-02-25	Alvine Pharmaceuticals, Inc.	Formulation for oral administration of proteins
CA2764635C (en) *	2009-06-09	2018-05-22	Lux Biosciences, Inc.	Topical drug delivery systems for ophthalmic use
SG177536A1 (en)	2009-07-09	2012-03-29	Oshadi Drug Administration Ltd	Matrix carrier compositions, methods and uses
EP2461803B1 (de)	2009-08-03	2018-10-17	Emisphere Technologies, Inc.	Schnell wirkende naproxenzusammensetzung mit reduzierter wirkung auf magen und darm
US20110177147A1 (en) *	2010-01-21	2011-07-21	General Electric Company	Stable biocidal delivery systems
AU2011213175A1 (en) *	2010-02-04	2014-02-20	Michael M. Goldberg	Use of oral heparin preparations to treat urinary tract diseases and conditions
JP5894726B2 (ja) *	2010-07-13	2016-03-30	株式会社大塚製薬工場	膵島の分離方法および膵島組織を保護するための保護液
AU2012223282B2 (en)	2011-03-01	2017-02-02	Nutrition 21, Llc	Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
RU2495866C1 (ru) *	2012-06-19	2013-10-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации	Производное гамма-аминомасляной кислоты, обладающее ноотропной активностью в сочетании с транквилизирующим действием
RU2495867C1 (ru) *	2012-07-11	2013-10-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации"	Дилитиевая соль n-салицилоилглицина, обладающая ноотропной активностью
BR112015006176B1 (pt)	2012-09-21	2023-04-18	Intensity Therapeutics, Inc	Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
CA2908154C (en)	2013-04-29	2023-11-28	Memorial Sloan Kettering Cancer Center	Compositions and methods for altering second messenger signaling
EP3413900A1 (de)	2016-02-11	2018-12-19	Nutrition 21, LLC	Chromhaltige zusammensetzungen zur verbesserung der gesundheit und fitness
RU2633769C1 (ru) *	2016-05-16	2017-10-18	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ГБОУ ВПО ВолгГМУ МЗ РФ	Гамма-(N-гидроксибензоиламино)бутирохлориды, как полупродукты для получения потенциальных биологически активных производных гамма-аминомасляной кислоты
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
CN108689876B (zh) *	2018-06-28	2020-11-27	苏州东南药业股份有限公司	一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR4446E (fr)	1904-07-05	1905-08-25	Jacques Pinatel	Étau serrant les pièces coniques
US3489793A (en) *	1966-05-16	1970-01-13	Francia Formaceutici S R L	New benzamido butyric acid derivatives
ES369853A1 (es)	1969-07-24	1971-07-16	Bama S A Lab	Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
DE2260118C2 (de) *	1972-12-08	1982-06-03	Bayer Ag, 5090 Leverkusen	Penicilline sowie ihre Verwendung als Arzneimittel
DE2517229A1 (de) *	1975-04-18	1976-10-28	Boehringer Mannheim Gmbh	Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
NZ196349A (en) *	1980-03-07	1984-08-24	Interx Research Corp	Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) *	1980-11-09	1984-04-10	Kyoto Yakuhin Kogyo Kabushiki Kaisha	Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) *	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
GB2092136B (en) *	1981-01-17	1985-06-05	Mitsui Toatsu Chemicals	Production of n-substituted amide compounds
JPS58140026A (ja) *	1982-01-14	1983-08-19	Toyo Jozo Co Ltd	吸収性良好な製剤
FR2509175B1 (fr)	1981-03-06	1987-01-16	Toyo Jozo Kk	Preparation therapeutique ayant d'excellentes proprietes d'absorption
DE3266360D1 (en) *	1981-06-16	1985-10-24	Choay Sa	Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation
JPS611651A (ja)	1984-06-12	1986-01-07	Toyama Chem Co Ltd	Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
US4757066A (en) *	1984-10-15	1988-07-12	Sankyo Company Limited	Composition containing a penem or carbapenem antibiotic and the use of the same
LU86258A1 (fr) *	1986-01-21	1987-09-03	Rech Dermatologiques C I R D S	Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) *	1986-08-18	1998-07-28	Emisphere Technologies, Inc.	Delivery systems for pharmacological agents encapsulated with proteinoids
FR2636238B1 (fr) *	1988-09-14	1994-01-21	Morelle Jean	Nouvelles compositions antisudorales
JPH02239980A (ja)	1989-03-15	1990-09-21	Fuji Photo Film Co Ltd	感熱記録材料
US5714167A (en)	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
US5541155A (en) *	1994-04-22	1996-07-30	Emisphere Technologies, Inc.	Acids and acid salts and their use in delivery systems
US5451410A (en) *	1993-04-22	1995-09-19	Emisphere Technologies, Inc.	Modified amino acids for encapsulating active agents
US5443841A (en) *	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US6099856A (en) *	1992-06-15	2000-08-08	Emisphere Technologies, Inc.	Active agent transport systems
US6344213B1 (en)	1996-03-29	2002-02-05	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5629020A (en)	1994-04-22	1997-05-13	Emisphere Technologies, Inc.	Modified amino acids for drug delivery
US6221367B1 (en) *	1992-06-15	2001-04-24	Emisphere Technologies, Inc.	Active agent transport systems
US5447728A (en) *	1992-06-15	1995-09-05	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5811127A (en) *	1992-06-15	1998-09-22	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
HU211995B (en) *	1992-06-30	1996-01-29	Gyogyszerkutato Intezet	Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5583020A (en)	1992-11-24	1996-12-10	Ribozyme Pharmaceuticals, Inc.	Permeability enhancers for negatively charged polynucleotides
US5401516A (en) *	1992-12-21	1995-03-28	Emisphere Technologies, Inc.	Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
EP1077070A3 (de) *	1993-04-22	2001-05-23	Emisphere Technologies, Inc.	Orale Darreichungsform
US5709861A (en) *	1993-04-22	1998-01-20	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US5643957A (en) *	1993-04-22	1997-07-01	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6461643B2 (en) *	1993-04-22	2002-10-08	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5958457A (en) *	1993-04-22	1999-09-28	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US20010003001A1 (en) *	1993-04-22	2001-06-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5935610A (en) *	1993-08-26	1999-08-10	Mclean; Linsey	Composition having buffering properties
IL115693A (en) *	1994-10-25	2000-08-13	Revlon Consumer Prod Corp	Cosmetic compositions with improved transfer resistance
US6090958A (en) *	1995-03-31	2000-07-18	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
BR9604880A (pt) *	1995-03-31	1998-05-19	Emisphere Tech Inc	Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en) *	1995-03-31	1999-12-14	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5650386A (en) *	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
US5866536A (en) *	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5989539A (en) *	1995-03-31	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
GB2320248B (en)	1995-09-11	1999-04-14	Emisphere Tech Inc	Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
IL118657A0 (en)	1996-06-14	1996-10-16	Arad Dorit	Inhibitors for picornavirus proteases
EP0886471A4 (de) *	1996-11-18	2002-07-17	Emisphere Tech Inc	Verfahren und zusammensetzungen zur induzierung oraler toleranz in saugetieren
US5879681A (en) *	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
ATE383169T1 (de) *	1997-02-07	2008-01-15	Emisphere Tech Inc	Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US6051561A (en) *	1997-02-07	2000-04-18	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US6313088B1 (en) *	1997-02-07	2001-11-06	Emisphere Technologies, Inc.	8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5773647A (en) *	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5876710A (en) *	1997-02-07	1999-03-02	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US6060513A (en) *	1997-02-07	2000-05-09	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5939381A (en) *	1997-02-07	1999-08-17	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5990166A (en) *	1997-02-07	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5776888A (en) *	1997-02-07	1998-07-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5804688A (en) *	1997-02-07	1998-09-08	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6358504B1 (en) *	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5863944A (en) *	1997-04-30	1999-01-26	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5962710A (en) *	1997-05-09	1999-10-05	Emisphere Technologies, Inc.	Method of preparing salicyloylamino acids
CN1205994C (zh) *	1998-07-27	2005-06-15	艾米斯菲尔技术有限公司	经肺运送活性剂
US6440929B1 (en) *	1998-07-27	2002-08-27	Emisphere Technologies, Inc.	Pulmonary delivery of active agents
IL140930A0 (en) *	1998-08-07	2002-02-10	Emisphere Tech Inc	Compounds and compositions for delivering active agents
EP1146860A4 (de) *	1999-01-08	2002-07-03	Emisphere Tech Inc	Polymere arzneimittelabgabesysteme und -verbindungen
CA2361716C (en) *	1999-02-05	2009-04-28	Emisphere Technologies, Inc.	Method of preparing alkylated salicylamides
CA2364849A1 (en) *	1999-02-26	2000-08-31	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
ES2298168T3 (es) *	1999-12-16	2008-05-16	Emisphere Technologies, Inc.	Compuestos y composiciones para suministrar agentes activos.
US6384278B1 (en) *	2000-02-04	2002-05-07	Emisphere Technologies, Inc.	Boron-mediated amidation of carboxylic acids
WO2002019969A2 (en)	2000-09-06	2002-03-14	Emisphere Technologies Inc.	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EP1603869A1 (de) *	2003-03-11	2005-12-14	Pharmacia Corporation	Kristallines maleatsalz ii aus s- 2- (1-iminoethyl)aminoethyl -2-methyl-l-cystein

2001
- 2001-06-29 AU AU7315301A patent/AU7315301A/xx active Pending
- 2001-06-29 DE DE60133555T patent/DE60133555T2/de not_active Expired - Lifetime
- 2001-06-29 RU RU2003102615/04A patent/RU2326110C2/ru not_active IP Right Cessation
- 2001-06-29 CA CA002411754A patent/CA2411754C/en not_active Expired - Lifetime
- 2001-06-29 CN CNB018119182A patent/CN100482637C/zh not_active Expired - Lifetime
- 2001-06-29 US US10/312,703 patent/US7351741B2/en not_active Expired - Lifetime
- 2001-06-29 ES ES01952394T patent/ES2306719T3/es not_active Expired - Lifetime
- 2001-06-29 DK DK01952394T patent/DK1299348T3/da active
- 2001-06-29 MX MXPA02012855A patent/MXPA02012855A/es active IP Right Grant
- 2001-06-29 PT PT01952394T patent/PT1299348E/pt unknown
- 2001-06-29 UA UA2003010772A patent/UA80248C2/uk unknown
- 2001-06-29 WO PCT/US2001/021073 patent/WO2002002509A1/en active IP Right Grant
- 2001-06-29 KR KR1020027017966A patent/KR100828668B1/ko not_active IP Right Cessation
- 2001-06-29 BR BR0112311-4A patent/BR0112311A/pt active Search and Examination
- 2001-06-29 EP EP01952394A patent/EP1299348B1/de not_active Expired - Lifetime
- 2001-06-29 AT AT01952394T patent/ATE391708T1/de active
- 2001-06-29 NZ NZ523017A patent/NZ523017A/en not_active IP Right Cessation
- 2001-06-29 JP JP2002507766A patent/JP2004521857A/ja active Pending
- 2001-06-29 AU AU2001273153A patent/AU2001273153B2/en not_active Ceased
- 2001-06-29 CZ CZ20030275A patent/CZ303736B6/cs not_active IP Right Cessation
- 2001-06-29 SK SK118-2003A patent/SK1182003A3/sk unknown
- 2001-06-29 IL IL15329701A patent/IL153297A0/xx unknown
2002
- 2002-12-09 ZA ZA200209946A patent/ZA200209946B/en unknown
2003
- 2003-10-06 HK HK03107183A patent/HK1054918A1/xx not_active IP Right Cessation
2006
- 2006-02-17 AU AU2006200678A patent/AU2006200678B2/en not_active Ceased
2008
- 2008-06-19 CY CY20081100654T patent/CY1108532T1/el unknown

Also Published As

Publication number	Publication date
HK1054918A1 (en)	2003-12-19
CZ303736B6 (cs)	2013-04-17
JP2004521857A (ja)	2004-07-22
CN100482637C (zh)	2009-04-29
US7351741B2 (en)	2008-04-01
EP1299348A1 (de)	2003-04-09
ATE391708T1 (de)	2008-04-15
RU2326110C2 (ru)	2008-06-10
CA2411754A1 (en)	2002-01-10
SK1182003A3 (en)	2003-09-11
AU2001273153A2 (en)	2002-01-14
UA80248C2 (en)	2007-09-10
BR0112311A (pt)	2003-09-02
WO2002002509A1 (en)	2002-01-10
DE60133555D1 (de)	2008-05-21
KR20030058958A (ko)	2003-07-07
CA2411754C (en)	2009-05-26
EP1299348B1 (de)	2008-04-09
KR100828668B1 (ko)	2008-05-09
CN1460100A (zh)	2003-12-03
AU2001273153B2 (en)	2005-11-17
AU2006200678A1 (en)	2006-03-09
AU7315301A (en)	2002-01-14
AU2006200678B2 (en)	2009-01-15
CY1108532T1 (el)	2014-04-09
ES2306719T3 (es)	2008-11-16
NZ523017A (en)	2004-10-29
EP1299348A4 (de)	2005-07-20
PT1299348E (pt)	2008-05-12
DK1299348T3 (da)	2008-07-28
MXPA02012855A (es)	2004-04-20
AU2001273153C1 (en)	2002-01-14
IL153297A0 (en)	2003-07-06
DE60133555T2 (de)	2008-09-18
US20040048777A1 (en)	2004-03-11

Publication	Publication Date	Title
ZA200209946B (en)	2003-11-07	Compounds and compositions for delivering active agents.
EP1322595B1 (de)	2008-05-28	(5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
US7115663B2 (en)	2006-10-03	Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
US6646162B2 (en)	2003-11-11	Compounds and compositions for delivering active agents
AU2001273153A1 (en)	2002-04-11	Compounds and compositions for delivering active agents
EP1226109A2 (de)	2002-07-31	Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen
JP2001524109A (ja)	2001-11-27	活性剤を輸送するための化合物および組成物
ZA200403572B (en)	2005-09-28	Phenoxy amine compounds and compositions for delivering active agents
JP2003517438A (ja)	2003-05-27	活性剤のデリバリーのための化合物及び組成物
US20030220226A1 (en)	2003-11-27	Compounds and compositions for delivering active agents
EP2308479A2 (de)	2011-04-13	Verbindungen und Zusammensetzungen zur Wirkstofffreisetzung
AU2002245580A1 (en)	2003-03-13	Compounds and compositions for delivering active agents
WO2002100338A2 (en)	2002-12-19	Compound and composition for delivering active agents
US7279597B1 (en)	2007-10-09	Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AU2004201178A1 (en)	2004-04-22	Compounds and compositions for delivering active agents
ZA200202365B (en)	2002-10-25	Phenoxy carboxylic acid compounds and compositions for delivering active agents.
IL153297A (en)	2010-04-29	Compounds and compositions for delivering active agents